About
Dame Kate Bingham is a British venture capitalist and Managing Partner at SV Health Investors, where she has led and co-led biotech investing since 1991. She chaired the UK's Vaccine Taskforce from May to December 2020, helping shape the country's COVID-19 vaccine procurement and manufacturing strategy. She also serves on science and biotech boards including ARIA, the Francis Crick Institute, Alchemab, and EyeBio.
Areas of interest
biotechdrug discoveryvaccinespublic healthneurodegenerationdementiaoncologyophthalmologyprecision medicinelife sciences commercialization